Soligenix, Inc. (LON:0A6I)

Market Cap	6.18M
Revenue (ttm)	1.81K
Net Income (ttm)	-7.42M
Shares Out	n/a
EPS (ttm)	-3.29
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	28,340
Average Volume	105,342
Open	2.830
Previous Close	2.761
Day's Range	2.830 - 3.316
52-Week Range	1.105 - 5.360
Beta	n/a
RSI	54.72
Earnings Date	Aug 8, 2025

About Nuvei

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. It operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in Phase 3 clinical trial for the treatment of inflam...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1987
• Employees: 16
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0A6I

Financial Performance

In 2024, Soligenix's revenue was $119,371, a decrease of -85.78% compared to the previous year's $839,359. Losses were -$8.27 million, 34.6% more than in 2023.